

#### **Table of Contents**

```
Executive Summary (Slide 3)
Program Features (Slide 4)
Audience Generation (Slide 5)
Online Enduring Outcomes (Slide 6)
         Educational Impact Summary (Slide 7)
         Level 1 – Participation (Slides 8-10)
         Level 2 – Satisfaction (Slide 11-12)
         Level 3 & 4 - Knowledge and Competence (Slides 13-18)
         Level 4 – Competence (Slide 19-20)
         Level 5 – Performance (Slide 21)
         Evaluation Survey Results (Slide 22)
Live Webinars Outcomes (Slide 23)
         Educational Impact Summary (Slide 24)
         Level 1 – Participation (Slides 25-26)
         Level 2 – Satisfaction (Slide 27)
         Level 3 & 4 - Knowledge and Competence (Slides 28-31)
         Level 4 – Competence (Slide 32-33)
         Level 5 – Performance (Slide 34)
         Evaluation Survey Results (Slide 35)
Accreditation (Slide 36)
```



### **Executive Summary**



Cori Fratelli, BSN, RN, MS, FNP-C Nurse Practitioner Department of Medicine National Jewish Health Denver, CO



Corinne Young, FNP-C, FCCP President, Association of Pulmonary Advanced Practice Providers Colorado Springs, CO



Zulma Yunt, MD
Associate Professor of Medicine
Clinic Director, Interstitial Lung Disease Program
Medical Director, Office of Professional
Education
Department of Medicine
National Jewish Health
Denver, CO

#### **Program Overview**

This program was designed in collaboration with National Jewish Health and the Association of Pulmonary Advanced Practice Providers to engage NPs and PAs in the topic of CF-ILD with a progressive phenotype/progressive pulmonary fibrosis (PPF). A panel of nurse practitioners and a pulmonologist discuss the signs, symptoms and risk factors of CF-ILD with PPF, strategies for an early diagnosis, and effective communication strategies to improve health-care provider and patient engagement. The program utilized a combination of a live webinar and a video-based activity on the ArcheMedx platform with microlearning tactics to reinforce the education and improve retention. Other program features include a whiteboard animation to illustrate the pathophysiology of CF-ILD with PPF, an indepth review of radiologic imaging, and a panel discussion on interprofessional and multidisciplinary care as well as differences in community-based and specialty care for patients with CF-ILD with PPF.

#### **Learning Objectives**

- Utilize effective diagnostic strategies to identify and diagnose CF-ILD with PPF.
- Identify signs, symptoms, risk factors, and the clinical characteristics associated with CF-ILD with PPF.
- Apply effective communication strategies to improve healthcare provider and patient engagement.

#### **Target Audience & Accreditation**

Target Audience: Nurse Practitioners (NPs) and Physician Associates (PAs) who care for patients with ILD

NJH is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME). NJH designates the live webinar and online enduring activities for a maximum of .75 AMA PRA Category 1 Credits<sup>TM</sup> each.

#### **Live Webinars:**


June 22, 2023 & August 12, 2023

## Enduring activity on myCME / ArcheMedX June 30, 2023 – June 30, 2024


https://www.mycme.com/courses/advanced-providers-chronic-fibrosing-interstitial-lung-disease-8862


### **Program Features**

# Faculty Roundtable Discussion



### **Resources in ArcheMedx Platform**





98%

evaluation respondents reported the animation improved their understanding of the pathophysiology of CF-ILD

(N=414)




#### **Audience Generation**

Personalized targeting tools across numerous tactics reach HCPs by leveraging demographic data (such as location, profession, specialty) and behavioral data (such as learner participation history, areas of interest).



Emails and
e-newsletters sent to National
Jewish Health (NJH),
Association of Pulmonary
Advanced Practice Providers
(APAPP) and myCME
databases







Dedicated landing page on National Jewish Health website and myCME



Promotion of enduring activity at live conferences



### **Online Enduring**

#### Beyond the Basics: The Role of Advanced Practice Providers in Chronic Fibrosing ILD Care

CME | 0.75 Credits



#### **Program Description**

**Educational Objectives** 

Description

Chronic fibrosing ILD (CF-ILD) is a recently defined phenotypic subset of interstitial lung disease (ILD) characterized by worsening respiratory symptoms, declining lung function, limited responsiveness to immunomodulatory therapy, and potentially increased mortality. This program will focus on identifying signs, symptoms and risk factors of CF-ILD with a progressive fibrosing phenotype; strategies for early diagnosis; and effective communication strategies to improve healthcare provider and patient engagement.

CME/CE Information

Faculty and Disclosures

Instructions

#### Webcast

Time to Complete: 45 minutes

Released: June 30, 2023 Expires: June 30, 2024

Maximum Credits:

0.75 / AMA PRA Category 1 Credits<sup>TM</sup>


#### **Start Activity**


#### **EDUCATIONAL PARTNER**


This activity is hosted on the site of our educational partner, ArcheMedX, an award-winning learning and analytics platform dedicated to improving clinical care by increasing learner competence, improving knowledge retention, and accelerating practice change.




**Educational Impact Summary** 










Confidential

7

Participation Funnel – myCME and ArcheMedx



Guarantee	Actuals
1,000 learners	1,036 learners

75% of learners on myCME engaged with the content on ArcheMedx

#### **Mobile Use**




ArcheMedx learners who accessed the curriculum via a mobile device




Level 1 Outcomes: Participation (Degree)

### **Learners on myCME**




Degree	Total
MD/DO	312
NP	224
PA	118
Nurse	159
PharmD	20
Student	20
Other HCP	175
Other (Administrator, Consumer, etc)	8
Total Learners	1,036

#### **Learners on ArcheMedx**





Degree	Total
MD/DO	253
NP	178
PA	80
Nurse	112
PharmD	12
Student	16
Other HCP	113
Other (Administrator, Consumer, etc)	5
Not reported	9
Total Learners	778

Level 1 Outcomes: Participation (Specialty)




Confidential






Specialty	Tota
Pulmonary	156
Primary care	150
Internal medicine	90
Surgery	32
Critical care	28
Cardiology	19
Emergency medicine	20
Pediatrics	17
Geriatric medicine	12
Radiology	12
Hospital medicine	11
Allergy/Immunology	13
Other/Not reported	218
Total Learners	778

Level 2 Outcomes: Satisfaction



Learner Engagement while Viewing the Content



#### **Top Resources Viewed and Downloaded**

#### Viewed

ILD Chart resource

Idiopathic Pulmonary Fibrosis Update resource

Radiology Review video

CF-ILD Panel Discussion video

#### **Downloaded**

ILD Chart resource


Idiopathic Pulmonary Fibrosis Update resource

Radiology Review video and slides


Communicating with Patients - MedlinePlus Med Encyclopedia




Level 3 & 4: Knowledge and Competence - Assessment by Learning Objectives



### Level 3 & 4: Knowledge and Competence – Confidence-Based Assessment



#### **Aggregate Assessment Scores**



RISE IN MASTERY

Relative Increase in Learners who show High Confidence and Correctness

**AVERAGE NUMBER OF POST-TEST ATTEMPTS** 




**Paired Tests** 

Level 3 & 4: Knowledge and Competence – Assessment Questions

Question 1: What is the most effective diagnostic strategy to identify and diagnose CF-ILD with progressive pulmonary fibrosis?

Learning Objective: Utilize effective diagnostic strategies to identify and diagnose CF-ILD with PPF






### Level 3 & 4: Knowledge and Competence – Assessment Questions

Question 2: A patient with ILD calls into your office reporting three weeks of worsening shortness of breath. There is no current fever, but the patient feels like it started with "a cold." The patient has noticed lower oxygen levels with walking his dog for the past week. He denies other systemic symptoms. The air quality has been extremely poor, and the patient suspects that this may be affecting his breathing. Your next course of action should be:

Learning Objective: Identify signs, symptoms, risk factors, and the clinical characteristics associated with CF-ILD with PPF




Confidential


Level 3 & 4: Knowledge and Competence – Assessment Questions

Question 3: Which of the following statements reflects an effective strategy for communicating with a patient with CF-ILD?

Learning Objective: Apply effective communication strategies to improve healthcare provider and patient engagement



Level 3 & 4: Knowledge and Competence –CBA by Correctness




#### **Insights**

The chart shows changes in correctness and corresponding confidence-based assessment categories for each module and in total for the curriculum. All modules showed significant improvements in baseline pre- to first post-test as well as improvements in confidence across each module, with increases in Mastery (correctness with high confidence). One of the key elements in utilizing CBA is identifying learners who are guessing on the tests. These learners demonstrate a lack of knowledge or competence and can impact data significantly. For this initiative, there was a decrease for each learning objective on learners who were guessing, with the overall amount decreasing by 80%.

### Level 4 Outcomes: Competence

How likely are you to make changes in your practice?




# What changes will you incorporate into your practice as a result of what you learned?

- Consider this condition with progressive worsening with shortness of breath.
- · Order high resolution CT scan sooner.
- More aggressive diagnostic screening/testing.
- Narrowing down my diagnosis specific to ILD.
- Dealing differently with acute exacerbation of CF-IPF and initial diagnostic approach.
- Making sure ILD patients follow up every 3 months.
   Ensuring they receive a 6MWT and PFTs every 3-4 months to assess for disease progression.
- Better communication with patients about their disease expectations.
- Incorporate more education during follow-up visits.
- More in-depth review of last visit, including radiographs or lab results.



### Level 4 Outcomes: Competence

After having participated in this activity, how confident are you in your ability to: (% Very confident / Somewhat confident)



■ Post-confidence (n=394) ■ Pre-confidence (n=647)



Level 5 Outcomes: Performance

#### 45-Day Follow-up Survey


While the response rate to the follow-up survey was low with only two respondents, their responses indicate that participation in the activity has made a positive impact on their practice and their patients.

# What change(s) have you incorporated into practice as a result of this activity?




"Early detection of diagnosis." "Initiate early treatment."

Barriers to optimal patient care encountered in practice since the activity







### **Evaluation Survey Results**

### **Key Takeaways**

- Communicating effectively and the importance of follow up and repeat testing to assess for progression of disease
- Close follow-up of patients and evaluation for progression of disease
- Evaluating for progression on a regular basis and obtaining a 6 MWT at each visit
- Importance of interdisciplinary approach to communicating with patients
- Looking for ground glass patterns on chest radiographs
- Strategies for communicating with patients
- · Going over diagnosis and treatment plan each time you interact with patient

### **Future Topics**

- HRCT features
- Different types of antifibrotic therapies and the risks/benefits of starting therapy
- More clinical case-based activities
- Radiological differences and treatment of ILD
- Anti-fibrotics in IPF and PPF
- · Therapies on the horizon for ILD
- More guidance on educating patients




#### **Live Webinars**










**Educational Impact Summary** 







Evaluation respondents reported gaining strategies for overcoming barriers to optimal patient care




**Confidence Across Objectives** 

Evaluation respondents intend to make changes to practice as a result of the activity

patients (100%)

Level 1 Outcomes: Participation (Degree)




Degree	Total
MD/DO	12
NP	19
PA	7
PharmD	4
Other	10
<b>Total Completers</b>	52

73% of completers were physicians and advanced practice providers




Level 1 Outcomes: Participation (Specialty)



Degree	Total
Pulmonary	35
Family Practice	4
Pediatrics	2
Other	11
<b>Total Completers</b>	52





Level 2 Outcomes: Satisfaction



Level 3 & 4 Outcomes: Knowledge and Competence

### Overall Knowledge Gain across Learning Objectives








Level 3 & 4 Outcomes: Knowledge and Competence

Learning Objective: Utilize effective diagnostic strategies to identify and diagnose CF-ILD with PPF.


Question 1: What is the most effective diagnostic strategy to identify and diagnose CF-ILD with PPF?



Level 3 & 4 Outcomes: Knowledge and Competence

Learning Objective: Identify signs, symptoms, risk factors, and the clinical characteristics associated with CF-ILD with PPF.

**Question 2:** A patient with ILD calls into your office reporting three weeks of worsening shortness of breath. There is no current fever, but the patient feels like it started with "a cold". The patient has noticed lower oxygen levels with walking his dog for the past week. He denies other systemic symptoms. The air quality has been extremely poor, and the patient suspects that this may be affecting his breathing. Your next course of action should be:



Level 3 & 4 Outcomes: Knowledge and Competence


**Learning Objective:** Apply effective communication strategies to improve healthcare provider and patient engagement.

**Question 3:** Which of the following is the most effective strategy for communicating with a patient with CF-ILD?



■ Post Test (N=20)

Note: Upon review of the data, faculty revised this question for the enduring activity to ensure it was challenging enough to accurately measure change in knowledge.



0% 0% 0% 0% 0% 0%

Avoid discussing difficult topics that may upset your patient unless they bring it up

Discuss hospice only when the patient is nearing death and all options have been exhausted

Because there is so much information and education that your patient needs, don't waste time reviewing previous visits

Review previous visits and ask if there are any outstanding questions to help you assess your patient's understanding and help your patient feel supported



Level 4 Outcomes: Competence

Evaluation respondents reported their confidence as it relates to the learning objectives after the activity ("Very Confident" to "Somewhat Confident")

Apply effective communication strategies to improve healthcare provider and patient engagement?

Identify signs, symptoms, risk factors, and the clinical characteristics associated with CF-ILD with PPF?

Utilize effective diagnostic strategies to identify and diagnose CF-ILD with progressive pulmonary fibrosis (PPF)?






Level 4 Outcomes: Competence

# What change(s) will you incorporate into your practice as a result of what you learned in the activity?

- Identifying patients sooner
- Better understanding of CT Chest findings
- Earlier follow-up with HRCT for symptom change
- Order more HRCTs when appropriate
- Use more CT imaging
- Broadening of autoimmune testing
- Incorporating more 6MWT and autoimmune screening
- I plan on increasing my frequency of PFTs for CF-ILD patients
- I will follow evidence-based protocols for my patients
- Will change my management and intervention strategies
- Improving my discussion with patients





Level 5 Outcomes: Performance

#### 45-Day Follow-up Survey

While the response rate to the follow-up survey was low with only one respondent, their responses indicate that participation in the activity has made a positive impact on their practice and their patients.

# What change(s) have you incorporated into practice as a result of this activity?



"Incorporated different diagnostic strategies into patient evaluation."

# Confidence as it relates to the learning objectives 45-days post-activity

Apply effective communication strategies to improve healthcare provider and patient engagement?

Identify signs, symptoms, risk factors, and the clinical characteristics associated with CF-ILD with PPF?

Utilize effective diagnostic strategies to identify and diagnose CF-ILD with progressive pulmonary fibrosis (PPF)?

Very confident

Very confident

Somewhat confident

Of my patients have benefited from the information I learned in the activity Patients seen per week who are affected by CF-ILD The activity provided information, tools and resources to address the barriers to optimal patient care that I have faced since participating.

**National Jewish** 

**Evaluation Survey Results** 

### **Key Takeaways**

- CT imaging is critical
- Follow evidence-based protocols
- Improvement in analyzing imaging
- Treatment strategies

### **Future Topics**

- More ESG topics
- Rheumatological/Serological work up
- Terminal/hospice care
- Treatment options and when to start
- Treatment strategies

"This is a great lecture that is very informative. I really liked the interaction with the speakers. It made the topic more interesting."

Learner Feedback



### **Accreditation Details**

National Jewish Health is accredited with Commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The NJH Office of Professional Education produced and accredited this program and adhered to the updated ACCME guidelines.

National Jewish Health designates the live and enduring activities for a maximum of 0.75 *AMA PRA Category 1 Credit*™.



